A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is investigating a treatment called vutrisiran for people with a heart condition known as transthyretin amyloidosis (ATTR cardiomyopathy). This condition causes abnormal protein deposits to build up in the heart, making it harder for the heart to work properly. The main goal of this research is to gather more information about how safe and helpful vutrisiran is for patients who have previously been involved in other studies with vutrisiran or a similar medication called patisiran. Researchers will be looking at how well the medicine works and any side effects people might experience during the study.
A colpo d'occhio
Di cosa tratta questo studio?
This research study is about a condition called transthyretin amyloidosis (ATTR) with cardiomyopathy. Cardiomyopathy means that the heart muscle has become diseased, making it harder for the heart to pump blood effectively. In ATTR, a protein called transthyretin misfolds and builds up into deposits, known as amyloid, in various organs, including the heart. These amyloid deposits stop the heart from working as it should.
The study is focusing on a specific medicine called vutrisiran. This treatment is being looked at to see how well it works and if it's safe for people who have this particular heart condition. Researchers want to understand if vutrisiran can help manage the condition and improve the lives of patients.
Specifically, this study is for individuals who have already been taking vutrisiran in a previous study or who have switched to vutrisiran from another similar medication called patisiran. By continuing to monitor these patients, the researchers hope to gain more long-term information about vutrisiran's effects, gather further safety data, and assess its overall effectiveness in a real-world setting.
Punti chiave
- This study focuses on a heart condition called ATTR cardiomyopathy.
- It investigates the safety and effectiveness of a medicine called vutrisiran.
- This is for patients who have already used vutrisiran or similar treatments in prior studies.
- It's a Phase 3 study, a later stage of drug development.
- The aim is to gather more long-term information on the treatment.
Chi può essere idoneo?
To be considered for this study, you must have previously taken part in one of the parent studies for patisiran (ALN-TTR02-011 or ALN-TTR02-014) or completed an extended treatment period in the vutrisiran parent study (ALN-TTRSC02-003).
There are also some reasons why you might not be able to join. For example, if you stopped taking the study medication permanently in those earlier studies, you wouldn't be able to participate. You also can't be involved in another research study for a new drug or device at the same time as this one.
Finally, if you have other health conditions that the study doctors believe would make it difficult for you to follow the study rules or for them to understand your results, you might not be eligible.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Have I previously participated in a study for patisiran (ALN-TTR02-011 or ALN-TTR02-014)?
- Have I completed the 24-month treatment period in the vutrisiran parent study (ALN-TTRSC02-003)?
- Have I permanently stopped taking the study drug in any of those previous studies?
- Am I currently or planning to be in another research study for a new drug or device?
Cosa comporta la partecipazione?
The detailed involvement in this study would be explained fully by the study team. As this study is for patients who have already been taking vutrisiran or patisiran, it is likely to involve continued monitoring of your health and the effects of vutrisiran. This would typically include regular visits to the study clinic, where you might have physical examinations, blood tests, and other assessments to check your heart function and overall health. You would continue to receive vutrisiran as part of the study. The total duration of your participation would be clearly outlined by the study team.
Rischi e benefici potenziali
Locations (87)
- Clinical Trial SiteCodice postale verificatoPhoenix, Stati Uniti
- Clinical Trial SiteCodice postale verificatoBeverly Hills, Stati Uniti
- Clinical Trial SiteCodice postale verificatoLa Jolla, Stati Uniti
- Clinical Trial SiteCodice postale verificatoStanford, United States
- Clinical Trial SiteCodice postale verificatoWashington D.C., Stati Uniti
- Clinical Trial SiteCodice postale verificatoChicago, Stati Uniti
- Clinical Trial SiteCodice postale verificatoGlenview, United States
- Clinical Trial SiteCodice postale verificatoIndianapolis, Stati Uniti
- Clinical Trial SiteCodice postale verificatoKansas City, Stati Uniti
- Clinical Trial SiteCodice postale verificatoBaltimora, Stati Uniti
- Clinical Trial SiteCodice postale verificatoBoston, Stati Uniti
- Clinical Trial SiteCodice postale verificatoBoston, Stati Uniti
Domande comuni
What is ATTR cardiomyopathy?
ATTR cardiomyopathy is a heart condition where special proteins called transthyretin misfold and build up in your heart, making it harder for your heart to work properly.
What is vutrisiran?
Vutrisiran is a medicine being studied as a treatment for ATTR cardiomyopathy. This study aims to understand its safety and effectiveness.
Can anyone with ATTR cardiomyopathy join this study?
No, this specific study is for people who have already taken part in previous studies involving vutrisiran or a similar medication called patisiran.
Cosa significa 'Fase 3' per uno studio?
Phase 3 means the study is in a later stage of research, where the medicine has already shown some promise. It involves a larger number of patients to confirm how well it works and its safety before it can be approved for general use.
Dovrò pagare per partecipare allo studio?
Generally, clinical trials cover the costs of study-related medication and procedures. This would be fully explained to you before you agree to participate.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.